DERIVATIVES OF [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE WITH AFFINITY TO CANNABINOID RECEPTORS OF TYPE 2 Russian patent published in 2021 - IPC C07D487/04 A61K31/519 A61P29/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to compounds of formula (I) and use thereof for detecting or visualizing CB2 receptors. In formula (I), R¹ is a ring selected from phenyl and [1,2,5]oxadiazolyl, where said ring is substituted with one substitute selected from halosulphonyl, halosulphonyl-C_1-8-alkyl, isothiocyanato-C_1-8-alkyl, isothiocyanato, amino-C_1-8-alkyldisulfanyl-C_1-8-alkyl, hydroxy-C_1-8-alkylsulphanyl-C_1-8-alkyl, hydroxy-C_1-8-alkyl disulphanyl, amino-C_1-8-alkyl disulphanyl, halogen, C_1-8-alkyl, pyridinyl disulphanyl-C_1-8-alkyl, benzotriazolylsulfonyl-C_1-8-alkyl, dihydroxy-C_1-8-alkylsulphanyl-C_1-8-alkyl and pyridinylsulphanyl and optionally further substituted with cyano; R² and R³ are independently selected from hydrogen, hydroxyl, halogen, thiohydroxyl, azido, isothiocyanato and C_1-8-alkyldisulfanyl; provided that at least one of R¹, R² and R³ is a group containing sulphonyl, isothiocyanato, disulphanyl, thiohydroxyl or azido; R⁴ is C_1-8-alkyl or phenyl-di-halogen-C-_1-8-alkyl; and n is 0 or 1. Invention also relates to a pharmaceutical composition for modulating CB2 receptors containing an effective amount of said compound of formula (I) and a therapeutically inert carrier.

EFFECT: disclosed are derivatives of [1,2,3]triazolo[4,5-d]pyrimidine with affinity for type 2 cannabinoid receptors.

12 cl, 39 ex